CGT | 바이오모아

CGTBiologicstaleSeoul National University Hospi…Phase 2

SNUH-CD19-CAR-T (SNUH-CD19-CAR-T)

Very High Risk Acute Lymphoblastic Leukemia; CD19 CAR-T Therapy · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleWashington University School of…Phase 2

TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft (TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft)

AML, Childhood; Aml · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5

CGTBiologicstaleChinese PLA General HospitalPhase 2

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell)

Acute Lymphocytic Leukemia · CD19

CGTBiologicstaleChinese PLA General HospitalPhase 2

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Non-hodgkin Lymphoma · CD19

CGTBiologicstaleUniversity of Wisconsin, MadisonPhase 1

TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC, TCRαβ+/CD19+ depleted Hematopoietic stem cell, TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft)

Blood Disease · CD19

CGTBiologicstaleEdiGene Inc.Phase 2

TRAC and Power3 (SPPL3, TRAC and Power3, TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T))

Non Hodgkin's Lymphoma · CD19

CGTBiologicstaleTimmune Biotech Inc.Phase 2

TriCAR-T-CD19 (TriCAR-T-CD19)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleBioray LaboratoriesPhase 1

Universal BCMA-CD19 CART (Universal BCMA-CD19 CART)

Autoimmune Disease · CD19

CGTBiologicstaleChinese PLA General HospitalPhase 2

Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells (Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleXijing HospitalPhase 1

XYF19 CAR-T cell (XYF19 CAR-T cell)

Leukemia Lymphocytic Acute (ALL) in Relapse; Leukemia Lymphocytic Acute (All) Refractory · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

CGTBiologicstaleChengdu Ucello Biotechnology Co…Phase 1

allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA (allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA)

SLE - Systemic Lupus Erythematosus · CD19

CGTBiologicstaleChangzhou No.2 People's HospitalPhase 1

KN5501 (anti-CD19 CAR NK cells, anti-CD19 CAR NK cells (KN5501))

Thrombocytopenia Alloimmune · CD19

CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

효능 ORR 0%임상시험 1상태 RECRUITING

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

CGTBiologicstaleThe First Affiliated Hospital o…Phase 2

anti-CD19 and anti-BCMA CAR (anti-CD19 and anti-BCMA CAR)

Safety and Efficacy · CD19

CGTBiologicstaleNational University Health Syst…Phase 1

anti-CD19 redirected NK cells (anti-CD19 redirected NK cells)

B-cell Acute Lymphoblastic Leukemia · CD19

CGTBiologicstaleShanghai First Song Biotechnolo…Phase 1

임상시험 1상태 DISCONTINUED

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

CGTBiologicstaleChinese PLA General HospitalPhase 2

anti-CD19/22-CAR vector-transduced T cells (anti-CD19/22-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5

CGTBiologicstaleGracell Biotechnologies (Shangh…Preclinical

CHT105 (anti-CD19/70 CAR T cells, anti-CD19/70 CAR T cells (CHT105))

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+4

CGTBiologicstaleJieyang People's HospitalPhase 1

anti-CD19/BCMA CAR NK cells (anti-CD19/BCMA CAR NK cells)

IgA Nephropathy (IgAN) · CD19